Seizure Disorders in Adults

Epilepsy encompasses a diverse group of disorders characterized by recurrent unprovoked seizures and requires careful evaluation to classify seizure type, identify underlying etiology, and distinguish epileptic events from common mimicking conditions. The International League Against Epilepsy classification provides a standardized framework that separates seizures into focal, generalized, or unknown classes, improving diagnostic consistency across care settings. Accurate identification is essential because misdiagnosis can lead to unnecessary treatment, inappropriate restrictions, and delayed care for the true underlying condition. The most common seizure mimics are syncope, psychogenic nonepileptic attacks (functional neurologic disorder), migraine with aura, transient ischemic attack, movement disorders, metabolic disturbances, and sleep disorders. Epidemiologic studies indicate that epilepsy affects 5 to 9 per 1,000 people in high-income countries, with a higher incidence in older adults due to cerebrovascular disease, dementia and neurodegeneration, and metabolic or systemic disorders. Morbidity and mortality remain significant, with increased risk attributable to status epilepticus, sudden unexpected death in epilepsy, injuries, drowning, and comorbid medical conditions. Understanding of seizure classification, mimic differentiation, and long-term prognosis allows clinicians to provide accurate counseling, initiate appropriate workup, and facilitate specialist referral when needed.

Management of epilepsy requires an individualized, longitudinal approach that incorporates seizure type, recurrence risk, comorbidities, lifestyle, reproductive planning, and safety implications of recurrent seizures. Family physicians play a central role in early counseling, initial medication discussions, monitoring for adverse effects, and recognizing when referral for advanced therapies is warranted. Evidence shows that early initiation of maintenance antiseizure medication after a first unprovoked seizure lowers short-term recurrence but does not change long-term remission or mortality, underscoring the need for shared decision-making grounded in patient preferences and psychosocial or occupational needs. Because epilepsy is increasingly viewed as a heterogeneous group of disorders rather than a single entity, treatment must integrate mechanism-based medication selection, titration principles, therapeutic monitoring, and nonpharmacologic options such as dietary therapy, neuromodulation, and surgery. This section provides a primary care–focused overview of medication strategy, emphasizing when to start medication, how to choose and adjust therapy, and how to manage breakthrough seizures, drug resistance, and pregnancy-related issues.

Family physicians play a central role in the longitudinal management of epilepsy that extends beyond seizure control to address medication adherence, comorbidity screening, lifestyle counseling, and patient education. Antiseizure medication adherence should be assessed at every visit because nonadherence is associated with increased risk of seizure recurrence. All patients and caregivers should receive counseling regarding sudden unexpected death in epilepsy, ideally at or near the time of diagnosis. Achieving freedom from seizures, particularly from generalized tonic-clonic seizures, is the most effective strategy for reducing risk of sudden unexpected death in epilepsy. Regular screening for psychiatric comorbidities, especially depression and anxiety, is essential given the prevalence of these conditions in epilepsy and their impact on quality of life and treatment adherence. Lifestyle counseling should address sleep hygiene, stress management, alcohol moderation, and avoidance of other seizure triggers that can precipitate breakthrough seizures. Comprehensive epilepsy care also includes individualized safety counseling, seizure action planning, and guidance on driving restrictions and workplace accommodations under the Americans with Disabilities Act. Women of childbearing potential require targeted counseling regarding potential teratogenic risks of treatment, with valproate avoided when possible and lamotrigine or levetiracetam generally preferred.